Perrigo Company plc (NYSE:PRGO) Receives Average Rating of “Hold” from Analysts

Shares of Perrigo Company plc (NYSE:PRGO) have been given an average recommendation of “Hold” by the six analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $19.3333.

Several research analysts have issued reports on the company. Canaccord Genuity Group dropped their target price on Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday.

Perrigo Trading Down 2.3%

PRGO opened at $10.60 on Friday. The firm has a market cap of $1.47 billion, a P/E ratio of -0.81, a P/E/G ratio of 1.27 and a beta of 0.52. Perrigo has a 12 month low of $9.23 and a 12 month high of $28.43. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The stock has a 50-day moving average of $10.77 and a 200 day moving average of $13.20.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The company had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm’s revenue was down 7.2% on a year-over-year basis. During the same quarter last year, the business posted $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, research analysts forecast that Perrigo will post 2.14 EPS for the current year.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th will be given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 10.9%. The ex-dividend date is Friday, May 29th. Perrigo’s payout ratio is -8.85%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Bahl & Gaynor Inc. boosted its holdings in shares of Perrigo by 5.4% in the third quarter. Bahl & Gaynor Inc. now owns 2,087,075 shares of the company’s stock valued at $46,479,000 after purchasing an additional 107,774 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Perrigo by 1,495.6% in the fourth quarter. SG Americas Securities LLC now owns 134,433 shares of the company’s stock valued at $1,871,000 after purchasing an additional 126,008 shares during the period. Cooke & Bieler LP boosted its holdings in shares of Perrigo by 11.6% in the third quarter. Cooke & Bieler LP now owns 3,680,411 shares of the company’s stock valued at $81,963,000 after purchasing an additional 381,290 shares during the period. Diamond Hill Capital Management Inc. boosted its holdings in shares of Perrigo by 8.6% in the third quarter. Diamond Hill Capital Management Inc. now owns 1,797,746 shares of the company’s stock valued at $40,036,000 after purchasing an additional 142,363 shares during the period. Finally, Nicola Wealth Management LTD. boosted its holdings in shares of Perrigo by 38.4% in the third quarter. Nicola Wealth Management LTD. now owns 281,000 shares of the company’s stock valued at $6,257,000 after purchasing an additional 78,000 shares during the period. Hedge funds and other institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.